News
Posted on Monday 4 August 2025
Her Royal Highness The Princess Royal visited the University’s industrial partner in a Knowledge Transfer Partnership (KTP) project.
During the visit, Her Royal Highness was given a guided tour of the facilities and met team members from across the LabLogic Group, including York alumnus Dr
Tom Deakin and Knowledge Transfer Partnership (KTP) Associate Dr Katie Staunton-Mann.
The visit to the LabLogic Group was in recognition of The King’s Award for Enterprise in International Trade, the UK’s most prestigious business accolade.
It celebrated LabLogic’s continued international success and commitment to innovation in sectors including nuclear medicine, nuclear power, defence and drug discovery.
The University is the knowledge base in the KTP and LabLogic Systems is the industrial partner.
During the last decade, Targeted Alpha Therapies (TATs) for new innovative cancer treatments have demonstrated the potential to transform patient care, offering new treatments for aggressive cancers such as triple-negative breast cancer, pancreatic cancer and glioblastoma.
However, the quality control checks for these therapies are still in the early stages of development compared to the more established standards for gamma and beta-emitting radionuclides.
To address this, LabLogic commenced a KTP project in October 2024 with Dr Christian Diget in the University’s Nuclear Physics Group.
Funded in part by Innovate UK, this collaboration aims to develop the next generation of QC instruments specifically for alpha-emitting radionuclides.
The University’s Nuclear Physics Group brings extensive experience in sensor development and instrumentation, which will be crucial for modelling and optimising radiation detector performance for these new QC systems.
The King’s Award for Enterprise in International Trade recognises exceptional and sustained growth in overseas sales.